Systematic inflammatory diseases, including rheumatoid arthritis (RA), are associated with an increased risk of malignancies. However, the pathogenesis of spondyloarthritis (SpA), which includes both ankylosing spondylitis and psoriatic arthritis, is different from RA, and the risk of malignancy and sites involved may also be different. It is important to better understand associations of SpA with site-specific cancers to facilitate appropriate cancer screening. The goal of this review was to examine the association of SpA with malignancy and the potential impact of therapy for SpA on development of malignancy.
Keywords: Ankylosing spondylitis; Cancer; Malignancy; Psoriatic arthritis; Spondyloarthritis; Tumor necrosis factor inhibitors.
Copyright © 2020 Elsevier Inc. All rights reserved.